Literature DB >> 2091939

Establishment of stable mouse/human-human hybrid cell lines producing large amounts of anti-tetanus human monoclonal antibodies with high neutralizing activity.

M Kamei1, S Hashizume, N Sugimoto, K Ozutsumi, M Matsuda.   

Abstract

To establish stable hybrid cell lines producing human anti-tetanus antibody with high toxin-neutralizing activity, peripheral lymphocytes from humans hyperimmunized with tetanus toxoid were, after in vitro antigen stimulation, fused with a mouse/human heteromyeloma or human lymphoblastoid cell line and cloned. Unlike the IgM secretors (six clones), the IgG secretors we obtained (six clones) produced anti-tetanus human monoclonal antibodies with high neutralizing activity (the highest one, cell line G2, 4.3 IU/100 micrograms IgG). Appropriate combinations of three or four kinds of monoclonal antibodies of the IgG type resulted in markedly increased neutralizing activity comparable with that of anti-tetanus human polyclonal immunoglobulin preparations currently used clinically on the basis of toxin-specific IgG content. Five of these cell lines produced 10-20 micrograms of antibody per ml for more than 3 months. The cell line G2 produced 6 mg of antibody per day in serum-free medium in a 500-ml bioreactor in perfusion culture and 13-104 mg in a nude mouse. These cell lines satisfied, for the first time, the minimal requirements for applying human monoclonal antibodies to clinical use.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2091939     DOI: 10.1007/BF00151713

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  28 in total

1.  The production of monoclonal antibodies from human lymphocytes.

Authors:  D Kozbor; J C Roder
Journal:  Immunol Today       Date:  1983-03

2.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

3.  Requirement of at least two distinct monoclonal antibodies for efficient neutralization of tetanus toxin in vivo.

Authors:  J Mizuguchi; T Yoshida; Y Sato; F Nagaoka; S Kondo; T Matuhasi
Journal:  Naturwissenschaften       Date:  1982-12

4.  Requirements for the establishment of high-titered human monoclonal antibodies against tetanus toxoid using the Epstein-Barr virus technique.

Authors:  D Kozbor; J C Roder
Journal:  J Immunol       Date:  1981-10       Impact factor: 5.422

5.  Antigenic substructure of tetanus neurotoxin.

Authors:  M Matsuda; M Yoneda
Journal:  Biochem Biophys Res Commun       Date:  1977-07-11       Impact factor: 3.575

6.  Characterization of human hybridomas secreting antibody to tetanus toxoid.

Authors:  J W Larrick; K E Truitt; A A Raubitschek; G Senyk; J C Wang
Journal:  Proc Natl Acad Sci U S A       Date:  1983-10       Impact factor: 11.205

7.  Human-human hybridomas secreting antibodies specific to human lung carcinoma.

Authors:  H Murakami; S Hashizume; H Ohashi; K Shinohara; K Yasumoto; K Nomoto; H Omura
Journal:  In Vitro Cell Dev Biol       Date:  1985-10

8.  Protective human hybridoma antibody to tetanus toxin.

Authors:  F Gigliotti; R A Insel
Journal:  J Clin Invest       Date:  1982-12       Impact factor: 14.808

9.  Serodiagnosis of cancer, using porcine antigens recognized by human monoclonal antibody, HB4C5.

Authors:  S Hashizume; K Mochizuki; H Murakami; T Yano; K Yasumoto; K Nomoto
Journal:  Biotherapy       Date:  1989

10.  Isolation and purification by high performance liquid chromatography of a tetanus toxin fragment (fragment [A-B]) derived from mildly papain-treated toxin.

Authors:  K Ozutsumi; D L Lei; N Sugimoto; M Matsuda
Journal:  Toxicon       Date:  1989       Impact factor: 3.033

View more
  7 in total

1.  Scale-up and optimization of culture conditions of a human heterohybridoma producing serotype-specific antibodies to Pseudomonas aeruginosa.

Authors:  U Schürch; S J Cryz; A B Lang
Journal:  Appl Microbiol Biotechnol       Date:  1992-07       Impact factor: 4.813

2.  Comparative in vitro and in vivo assessment of toxin neutralization by anti-tetanus toxin monoclonal antibodies.

Authors:  Mehdi Yousefi; Roya Khosravi-Eghbal; Ahmad Reza Mahmoudi; Mahmood Jeddi-Tehrani; Hodjatallah Rabbani; Fazel Shokri
Journal:  Hum Vaccin Immunother       Date:  2013-10-14       Impact factor: 3.452

3.  Characteristics of toxin-neutralization by anti-tetanus human monoclonal antibodies directed against the three functional domains [A], [B] and [C] of the tetanus toxin molecule and a reliable method for evaluating the protective effects of monoclonal antibodies.

Authors:  M Matsuda; M Kamei; N Sugimoto; Y Ma; S Hashizume
Journal:  Eur J Epidemiol       Date:  1992-01       Impact factor: 8.082

4.  Enhanced production of human monoclonal antibodies by the use of fructose in serum-free hybridoma culture media.

Authors:  K Mochizuki; S Sato; M Kato; S Hashizume
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

5.  Contribution of Fc fragment of monoclonal antibodies to tetanus toxin neutralization.

Authors:  Somayeh Ghotloo; Mohammad Mehdi Amiri; Jalal Khoshnoodi; Ebrahim Abbasi; Mahmood Jeddi-Tehrani; Forough Golsaz-Shirazi; Fazel Shokri
Journal:  Neurotox Res       Date:  2019-11-13       Impact factor: 3.911

6.  Novel neutralizing human monoclonal antibodies against tetanus neurotoxin.

Authors:  Takeharu Minamitani; Karin Kiyose; Ryota Otsubo; Toshihiro Ito; Hiroki Akiba; Rika A Furuta; Tsuyoshi Inoue; Kouhei Tsumoto; Masahiro Satake; Teruhito Yasui
Journal:  Sci Rep       Date:  2021-06-09       Impact factor: 4.379

Review 7.  Epitope mapping of neutralising anti-SARS-CoV-2 monoclonal antibodies: Implications for immunotherapy and vaccine design.

Authors:  Somayeh Ghotloo; Faezeh Maghsood; Forough Golsaz-Shirazi; Mohammad Mehdi Amiri; Christiane Moog; Fazel Shokri
Journal:  Rev Med Virol       Date:  2022-04-08       Impact factor: 11.043

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.